These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Home Use of Day-and-Night Hybrid Closed-Loop Insulin Delivery in Suboptimally Controlled Adolescents With Type 1 Diabetes: A 3-Week, Free-Living, Randomized Crossover Trial. Tauschmann M, Allen JM, Wilinska ME, Thabit H, Acerini CL, Dunger DB, Hovorka R. Diabetes Care; 2016 Nov; 39(11):2019-2025. PubMed ID: 27612500 [Abstract] [Full Text] [Related]
6. Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial. Tauschmann M, Thabit H, Bally L, Allen JM, Hartnell S, Wilinska ME, Ruan Y, Sibayan J, Kollman C, Cheng P, Beck RW, Acerini CL, Evans ML, Dunger DB, Elleri D, Campbell F, Bergenstal RM, Criego A, Shah VN, Leelarathna L, Hovorka R, APCam11 Consortium. Lancet; 2018 Oct 13; 392(10155):1321-1329. PubMed ID: 30292578 [Abstract] [Full Text] [Related]
7. Day-and-night glycaemic control with closed-loop insulin delivery versus conventional insulin pump therapy in free-living adults with well controlled type 1 diabetes: an open-label, randomised, crossover study. Bally L, Thabit H, Kojzar H, Mader JK, Qerimi-Hyseni J, Hartnell S, Tauschmann M, Allen JM, Wilinska ME, Pieber TR, Evans ML, Hovorka R. Lancet Diabetes Endocrinol; 2017 Apr 13; 5(4):261-270. PubMed ID: 28094136 [Abstract] [Full Text] [Related]
8. Safety, efficacy and glucose turnover of reduced prandial boluses during closed-loop therapy in adolescents with type 1 diabetes: a randomized clinical trial. Elleri D, Biagioni M, Allen JM, Kumareswaran K, Leelarathna L, Caldwell K, Nodale M, Wilinska ME, Haidar A, Calhoun P, Kollman C, Jackson NC, Umpleby AM, Acerini CL, Dunger DB, Hovorka R. Diabetes Obes Metab; 2015 Dec 13; 17(12):1173-9. PubMed ID: 26257323 [Abstract] [Full Text] [Related]
9. Fully Closed-Loop Glucose Control Compared With Insulin Pump Therapy With Continuous Glucose Monitoring in Adults With Type 1 Diabetes and Suboptimal Glycemic Control: A Single-Center, Randomized, Crossover Study. Boughton CK, Hartnell S, Lakshman R, Nwokolo M, Wilinska ME, Ware J, Allen JM, Evans ML, Hovorka R. Diabetes Care; 2023 Nov 01; 46(11):1916-1922. PubMed ID: 37616583 [Abstract] [Full Text] [Related]
10. Unsupervised home use of an overnight closed-loop system over 3-4 weeks: a pooled analysis of randomized controlled studies in adults and adolescents with type 1 diabetes. Thabit H, Elleri D, Leelarathna L, Allen JM, Lubina-Solomon A, Stadler M, Walkinshaw E, Iqbal A, Choudhary P, Wilinska ME, Barnard KD, Heller SR, Amiel SA, Evans ML, Dunger DB, Hovorka R. Diabetes Obes Metab; 2015 May 01; 17(5):452-8. PubMed ID: 25492378 [Abstract] [Full Text] [Related]
11. CamAPS FX Hybrid Closed-Loop with Ultra-Rapid Lispro Compared with Standard Lispro in Adults with Type 1 Diabetes: A Double-Blind, Randomized, Crossover Study. Nwokolo M, Lakshman R, Hartnell S, Alwan H, Ware J, Allen JM, Wilinska ME, Evans ML, Hovorka R, Boughton CK. Diabetes Technol Ther; 2023 Dec 01; 25(12):856-863. PubMed ID: 37823892 [Abstract] [Full Text] [Related]
12. Pharmacokinetics of diluted (U20) insulin aspart compared with standard (U100) in children aged 3-6 years with type 1 diabetes during closed-loop insulin delivery: a randomised clinical trial. Ruan Y, Elleri D, Allen JM, Tauschmann M, Wilinska ME, Dunger DB, Hovorka R. Diabetologia; 2015 Apr 01; 58(4):687-90. PubMed ID: 25537835 [Abstract] [Full Text] [Related]